Formatech, Inc. Donates Services to Formulate and Fill TRACON Pharmaceuticals, Inc.'s TRC102 Compound under Its "Fillanthropy(TM) Program"

ANDOVER, Mass.--(BUSINESS WIRE)--Today, Formatech, Inc. announces the selection of Tracon Pharmaceuticals’ TRC102 clinical product as the next Fillanthropy™ Program candidate. Under this program, Formatech donates the services required to aseptically fill and finish one lot of the drug candidate to support Tracon’s upcoming clinical trials.

Back to news